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Effects of dopamine on graft function 
after kidney transplantation
Schnuelle et al., JAMA 2009; 302: 1067–1075
Early but growing preclinical and clinical literature suggests that 
donor pretreatment with certain agents may enhance outcomes 
following transplantation. These include methylprednisolone, 
antilymphocyte globulin, atorvastatin, and dopamine. The inves-
tigators of this study previously demonstrated that dopamine and 
norepinephrine administration to the donor was associated with 
fewer episodes of acute rejection and superior long-term graft sur-
vival. A new randomized trial by Schnuelle et al. was undertaken to 
more firmly establish cause and effect. This open-label, multicenter 
trial randomized heart-beating donors to receive or to not receive 
dopamine as a continuous infusion begun after confirmation of 
brain death, continued until cross-clamping, and titrated on the 
basis of hemodynamics. The two groups were similar with respect 
to all characteristics with one exception. The group randomized to 
dopamine had slightly less concomitant treatment with norepine-
phrine. Donor dopamine treatment significantly reduced use of 
dialysis after transplantation. Among recipients of kidneys from 
donors treated with dopamine, 66% did not require dialysis, 9% 
required only one session of dialysis, and 25% required multiple 
sessions of dialysis. Among recipients of kidneys from donors who 
were not treated with dopamine, 59% did not require dialysis, 5% 
required only one session of dialysis, and 35% required multiple ses-
sions of dialysis. Among recipients of kidneys from donors treated 
with dopamine, 85%, 83%, and 81% of the kidneys were function-
ing at 1, 2, and 3 years, respectively. Among recipients of kidneys 
from donors not treated with dopamine, 87%, 81%, and 75% of the 
kidneys were functioning at 1, 2, and 3 years, respectively. Interest-
ingly, the benefit appeared strongest among recipients who received 
kidneys with the longest cold ischemia time.
This trial demonstrated a 15% reduction in post-transplantation 
dialysis. The possibility that a type II error occurred must be consid-
ered, because the report does not state whether power was available to 
show a difference. Further study will be necessary to parse this out.
Lynda Szczech
Vascular endothelial growth factor 
and blood pressure regulation
Facemire et al., Hypertension 2009; 54: 652–658; doi:10.1161/
HYPERTENSIONAHA.109.129973
Vascular endothelial growth factor (VEGF) induces angiogenesis 
but also regulates vascular permeability, endothelial-cell survival, 
and hematopoiesis. The major receptors for VEGF are two related 
tyrosine kinases, VEGFR1 (Flt-1) and VEGFR2 (Flk-1), the latter 
mediating its angiogenic, mitogenic, and permeability-enhancing 
effects. As stimulation of angiogenesis by VEGF is critical in 
the growth and spread of various cancers, antibodies and small 
molecules targeting this factor and its associated signaling pathways 
are currently used in the treatment of a variety of human malignan-
cies. Interestingly, along with its actions on blood vessel growth and 
permeability, VEGF also has systemic hemodynamic effects. For 
example, acute infusions of VEGF cause vasodilation and hypoten-
sion, likely mediated by VEGFR2 and stimulation of nitric oxide 
(NO) synthesis and/or vasodilator prostanoids. Further, hyperten-
sion has emerged as one of the most common adverse effects of 
VEGF inhibitors in patients treated for malignancies. To elucidate 
the molecular mechanisms underlying the effects of VEGF on the 
systemic circulation and blood pressure, Facemire et al. adminis-
tered a specific monoclonal antibody against VEGFR2 to normal 
mice and found that it caused a rapid and sustained increase in 
blood pressure of about 10 mm Hg (Figure). The increase in blood 
pressure was associated with a significant reduction in renal renin 
mRNA expression and in urinary excretion of aldosterone. The anti-
VEGFR2 antibody also caused a marked decrease in the expression 
of endothelial and neuronal NO synthases in the kidney. Admin-
istration of the inhibitor of NO production Nω-nitro-l-arginine 
methyl ester (l-NAME) abolished the difference in blood pressure 
between the control and anti-VEGFR2-treated animals. These data 
thus suggest that VEGF, acting via VEGFR2, plays a critical role in 
the control of normal blood pressure by promoting NO synthase 
expression and NO activity. Interfering with this pathway is likely to 
be a mechanism underlying hypertension caused by anti angiogenic 
agents targeting VEGF.
Juan Oliver
Exploring novel aspects of the RAS  
in cellular immunology
Stegbauer et al., Proc Natl Acad Sci USA 2009; 106: 14942–14947; doi:10.1073/
pnas.0903602106
Platten et al., Proc Natl Acad Sci USA 2009; 106: 14948–14953; doi:10.1073/
pnas.0903958106
In immunological diseases, including systemic lupus erythema-
tosus, examination of the RAS has been mostly restricted to the 
potential of the RAS to modify the response to proinflammatory 
cytokines. Now, two articles explore novel aspects of the RAS in 
cellular immunology. Stegbauer et al. studied the role of the RAS 
in myelin-oligodendrocyte glycoprotein-induced experimental 
Blood pressure in mice treated with anti-VEGFR2 monoclonal antibody 
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autoimmune encephalomyelitis (MOG-EAE), a model mimicking 
many aspects of multiple sclerosis (MS). Quantitative real-time PCR 
analyses showed an upregulation of renin, angiotensin-converting 
enzyme, and angiotensin II type 1 receptor (AT1R) in the inflamed 
spinal cord and the immune system, including antigen-presenting 
cells (APCs). Treatment with the renin inhibitor aliskiren or the 
angiotensin II-converting enzyme (ACE) inhibitor enalapril, as well 
as preventive or therapeutic application of the AT1R antagonist losa-
rtan, resulted in a significantly ameliorated course of MOG-EAE. 
Blockade of AT1R did not directly impact T-cell responses but sig-
nificantly reduced the numbers of CD11b+ or CD11c+ APCs in 
immune organs and in the inflamed spinal cord. Additionally, AT1R 
blockade impaired the expression of CCL2, CCL3, and CXCL10, 
and reduced CCL2-induced APC migration. These findings sug-
gest a pivotal role of the RAS in autoimmune inflammation of the 
central nervous system, a conclusion supported by another study. 
Here, Platten et al. show that the RAS also plays a major role in 
T cells during autoimmunity, exemplified by MS and its animal 
model, experimental autoimmune encephalomyelitis (EAE). Using 
proteomics, they observed that the renin–angiotensin–aldosterone 
system is upregulated in brain lesions of MS. By further analyz-
ing the T-cell response, Platten et al. found that the angiotensin 
receptor AT1R (Figure) was induced in myelin-specific CD4+ 
T cells and monocytes during autoimmune neuro inflammation. 
Blocking angio tensin II production with ACE inhibitors or inhib-
iting angiotensin II signaling with AT1R blockers suppressed 
autoreactive TH1 and TH17 cells and promoted antigen-specific 
CD4+FoxP3+ regulatory T cells with inhibition of the canonical 
nuclear factor-κB1 transcription factor complex and activation of 
the alternative nuclear factor-κB2 pathway. Treatment with ACE 
inhibitors reversed the neurological sequelae of EAE. These exciting 
studies imply a direct role of the RAS in regulating T-cell responses 
and thereby influencing the outcome of immunological diseases.
The authors of both studies propose that modulation of the RAS 
may represent an attractive supplemental therapeutic strategy for 
application to human autoimmune diseases. 
Detlef Schlöndorff
Involvement of potassium 
channels in renal fibrosis
Grgic et al., Proc Natl Acad Sci USA 2009; 106: 14518–14523; doi:10.1073/
pnas.0903458106
Progressive renal fibrosis is a characteristic of many kidney dis-
eases that result in end-stage renal failure. In the diseased kidney, 
some renal fibroblasts derive from epithelial cells and some from 
the bone marrow, but since resident interstitial fibroblasts likely 
represent the major source of newly generated fibroblasts, inhi-
bition of their proliferation may provide a therapeutic strategy. 
Indeed, several molecules with antifibrotic properties, such as 
bone morphogenic protein 7, hepatocyte growth factor, and pir-
fenidone, have been proposed as potential therapies. A variety of 
studies suggest that fibroblast proliferation in the kidney is due 
to locally secreted fibrogenic chemokines, including transform-
ing growth factor-β1, platelet-derived growth factor (PDGF), 
connective tissue growth factor (CTGF), and basic fibroblast 
growth factor (bFGF). However, recent work suggests that ion 
channels play a role in cell proliferation by enhancing intracel-
lular Ca2+ signaling and affecting cell-cycle progression. In this 
regard, Ca2+-permeable cation channels and Ca2+-activated K+ 
channels (KCa) seem to be critical. Whereas the former directly 
mediate Ca2+ inflow, the latter regulate membrane potential and 
thus provide the driving force for Ca2+ entry. In particular, the 
intermediate-conductance KCa (KCa3.1) channel has been shown 
to promote mitogenesis in several tissues and cell lines. Interest-
ingly, mitogens such as bFGF, PDGF, and vascular endothelial 
growth factor (VEGF) upregulate KCa3.1, and pharmacological 
inhibition or knock-down of KCa3.1 suppresses mitogen-driven 
cell proliferation. Grgic et al. postulated that KCa3.1 channels 
promote renal fibroblast proliferation and development of renal 
tubulointerstitial fibrosis. They found that mitogenic stimula-
tion upregulated KCa3.1 in murine renal fibroblasts via a MEK-
dependent mechanism, and that selective blockade of KCa3.1 
inhibited fibroblast proliferation by G0/G1 arrest. In vivo, renal 
fibrosis induced by unilateral ureteral obstruction (UUO) was 
associated with a robust upregulation of KCa3.1 in the kidney. In 
addition, mice lacking KCa3.1 (KCa3.1−/−) showed a significant 
reduction in fibrotic marker expression, chronic tubulointerstitial 
damage, collagen deposition, and α-smooth muscle actin-positive 
(αSMA) cells in kidneys after UUO (Figure). Similarly, treatment 
with the selective KCa3.1 blocker TRAM-34 also attenuated pro-
gression of UUO. Thus, these results demonstrate that KCa3.1 is 
involved in renal fibroblast proliferation and fibrogenesis and sug-
gest that this ion channel may be a therapeutic target for treatment 
of fibrotic kidney disease.
Juan Oliver
Expression of AT1R in MS plaques.
Genetic deficiency of KCa3.1 attenuates progression of renal fibrosis after 
UUO in mice. Periodic acid-Schiff, collagen I/III, and αSMA staining from 
UUO kidneys of wild-type (KCa3.1
+/+) and KCa3.1 knockout (KCa3.1
−/−) mice.
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